4.7 Article

Production of recombinant human granulocyte macrophage-colony stimulating factor in rice cell suspension culture with a human-like N-glycan structure

Journal

PLANT BIOTECHNOLOGY JOURNAL
Volume 9, Issue 9, Pages 1109-1119

Publisher

WILEY
DOI: 10.1111/j.1467-7652.2011.00636.x

Keywords

plant-made pharmaceuticals; hGM-CSF; Oryza sativa; N-glycans; glycosyltransferase; RNA interference

Funding

  1. Ministry for Food, Agriculture, Forestry and Fisheries, Republic of Korea [609004-05-1-SB130]
  2. Ministry of Knowledge Economy of the Republic of Korea [10030122]
  3. Korea Institute of Industrial Technology(KITECH) [10030122] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

Ask authors/readers for more resources

The rice alpha-amylase 3D promoter system, which is activated under sucrose-starved conditions, has emerged as a useful system for producing recombinant proteins. However, using rice as the production system for therapeutic proteins requires modifications of the N-glycosylation pattern because of the potential immunogenicity of plant-specific sugar residues. In this study, glyco-engineered rice were generated as a production host for therapeutic glycoproteins, using RNA interference (RNAi) technology to down-regulate the endogenous alpha-1,3-fucosyltransferase (alpha-1,3-FucT) and beta-1,2-xylosyltransferase (beta-1,2-XylT) genes. N-linked glycans from the RNAi lines were identified, and their structures were compared with those isolated from a wild-type cell suspension. The inverted-repeat chimeric RNA silencing construct of alpha-1,3-fucosyltransferase and beta-1,2-xylosyltransferase (Delta 3FT/XT)-9 glyco-engineered line with significantly reduced core alpha-1,3-fucosylated and/or beta-1,2-xylosylated glycan structures was established. Moreover, levels of plant-specific alpha-1,3-fucose and/or beta-1,2-xylose residues incorporated into recombinant human granulocyte/macrophage colony-stimulating factor (hGM-CSF) produced from the N44 + Delta 3FT/XT-4 glyco-engineered line co-expressing ihpRNA of Delta 3FT/XT and hGM-CSF were significantly decreased compared with those in the previously reported N44-08 transgenic line expressing hGM-CSF. None of the glyco-engineered lines differed from the wild type with respect to cell division, proliferation or ability to secrete proteins into the culture medium.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available